Pharmacokinetics of Orally Administered Phenazopyridine in Goats With Obstructive Urolithiasis
ABSTRACT Background Phenazopyridine is used for ancillary pain management in the treatment of goats with obstructive urolithiasis. However, there are no published studies on the pharmacokinetics, safety, or efficacy of phenazopyridine in goats. Hypothesis/Objectives Determine the pharmacokinetic par...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Journal of Veterinary Internal Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jvim.70167 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849728250210680832 |
|---|---|
| author | Sienna L. Mitman Danielle A. Mzyk Blanca E. Camacho R. McAlister Council‐Troche Jennifer Davis Derek M. Foster Jennifer Halleran |
| author_facet | Sienna L. Mitman Danielle A. Mzyk Blanca E. Camacho R. McAlister Council‐Troche Jennifer Davis Derek M. Foster Jennifer Halleran |
| author_sort | Sienna L. Mitman |
| collection | DOAJ |
| description | ABSTRACT Background Phenazopyridine is used for ancillary pain management in the treatment of goats with obstructive urolithiasis. However, there are no published studies on the pharmacokinetics, safety, or efficacy of phenazopyridine in goats. Hypothesis/Objectives Determine the pharmacokinetic parameters of phenazopyridine after oral administration in goats with obstructive urolithiasis after tube cystostomy surgery. Animals Six male goats, ages 3 months to 4 years. Methods Prospective, observational study. Goats presenting to a veterinary institution diagnosed with obstructive urolithiasis underwent a tube cystostomy surgery. After surgery, phenazopyridine (4 mg/kg PO q12h) was administered. Plasma and urine samples were collected at predetermined intervals, and the concentration of phenazopyridine and clinically relevant metabolites was determined using ultra high‐performance liquid chromatography with mass spectrometry. The pharmacokinetic parameters were determined using non‐compartmental analysis. Results The harmonic mean terminal elimination plasma half‐life (T1/2), geometric mean maximum plasma concentration (Cmax), and area under the curve (AUC) were 0.5 h (0.22–1.57 h), 263.4 ng/mL (137.35–1047.88 ng/mL), and 0.69 h*ng/mL (0.10–2.99 h*ng/mL), respectively for phenazopyridine. The concentration of phenazopyridine in urine samples was below the limit of assay detection (1.5 ng/mL) in all but one sample. Conclusions and Clinical Importance Phenazopyridine was rapidly eliminated from plasma and did not concentrate at detectable levels in the urine after oral administration. |
| format | Article |
| id | doaj-art-c86d4c14526a4c89853df1f4425c60da |
| institution | DOAJ |
| issn | 0891-6640 1939-1676 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Veterinary Internal Medicine |
| spelling | doaj-art-c86d4c14526a4c89853df1f4425c60da2025-08-20T03:09:35ZengWileyJournal of Veterinary Internal Medicine0891-66401939-16762025-07-01394n/an/a10.1111/jvim.70167Pharmacokinetics of Orally Administered Phenazopyridine in Goats With Obstructive UrolithiasisSienna L. Mitman0Danielle A. Mzyk1Blanca E. Camacho2R. McAlister Council‐Troche3Jennifer Davis4Derek M. Foster5Jennifer Halleran6North Carolina State University, College of Veterinary Medicine Raleigh North Carolina USANorth Carolina State University, College of Veterinary Medicine, Department of Population Health and Pathobiology Raleigh North Carolina USANorth Carolina State University, College of Veterinary Medicine Raleigh North Carolina USAVirginia‐Maryland Regional College of Veterinary Medicine, Department of Biomedical Sciences and Pathobiology Blacksburg Virginia USAVirginia‐Maryland Regional College of Veterinary Medicine, Department of Biomedical Sciences and Pathobiology Blacksburg Virginia USANorth Carolina State University, College of Veterinary Medicine, Department of Population Health and Pathobiology Raleigh North Carolina USANorth Carolina State University, College of Veterinary Medicine, Department of Population Health and Pathobiology Raleigh North Carolina USAABSTRACT Background Phenazopyridine is used for ancillary pain management in the treatment of goats with obstructive urolithiasis. However, there are no published studies on the pharmacokinetics, safety, or efficacy of phenazopyridine in goats. Hypothesis/Objectives Determine the pharmacokinetic parameters of phenazopyridine after oral administration in goats with obstructive urolithiasis after tube cystostomy surgery. Animals Six male goats, ages 3 months to 4 years. Methods Prospective, observational study. Goats presenting to a veterinary institution diagnosed with obstructive urolithiasis underwent a tube cystostomy surgery. After surgery, phenazopyridine (4 mg/kg PO q12h) was administered. Plasma and urine samples were collected at predetermined intervals, and the concentration of phenazopyridine and clinically relevant metabolites was determined using ultra high‐performance liquid chromatography with mass spectrometry. The pharmacokinetic parameters were determined using non‐compartmental analysis. Results The harmonic mean terminal elimination plasma half‐life (T1/2), geometric mean maximum plasma concentration (Cmax), and area under the curve (AUC) were 0.5 h (0.22–1.57 h), 263.4 ng/mL (137.35–1047.88 ng/mL), and 0.69 h*ng/mL (0.10–2.99 h*ng/mL), respectively for phenazopyridine. The concentration of phenazopyridine in urine samples was below the limit of assay detection (1.5 ng/mL) in all but one sample. Conclusions and Clinical Importance Phenazopyridine was rapidly eliminated from plasma and did not concentrate at detectable levels in the urine after oral administration.https://doi.org/10.1111/jvim.70167analgesiacaprinepharmacologyurolithiasis |
| spellingShingle | Sienna L. Mitman Danielle A. Mzyk Blanca E. Camacho R. McAlister Council‐Troche Jennifer Davis Derek M. Foster Jennifer Halleran Pharmacokinetics of Orally Administered Phenazopyridine in Goats With Obstructive Urolithiasis Journal of Veterinary Internal Medicine analgesia caprine pharmacology urolithiasis |
| title | Pharmacokinetics of Orally Administered Phenazopyridine in Goats With Obstructive Urolithiasis |
| title_full | Pharmacokinetics of Orally Administered Phenazopyridine in Goats With Obstructive Urolithiasis |
| title_fullStr | Pharmacokinetics of Orally Administered Phenazopyridine in Goats With Obstructive Urolithiasis |
| title_full_unstemmed | Pharmacokinetics of Orally Administered Phenazopyridine in Goats With Obstructive Urolithiasis |
| title_short | Pharmacokinetics of Orally Administered Phenazopyridine in Goats With Obstructive Urolithiasis |
| title_sort | pharmacokinetics of orally administered phenazopyridine in goats with obstructive urolithiasis |
| topic | analgesia caprine pharmacology urolithiasis |
| url | https://doi.org/10.1111/jvim.70167 |
| work_keys_str_mv | AT siennalmitman pharmacokineticsoforallyadministeredphenazopyridineingoatswithobstructiveurolithiasis AT danielleamzyk pharmacokineticsoforallyadministeredphenazopyridineingoatswithobstructiveurolithiasis AT blancaecamacho pharmacokineticsoforallyadministeredphenazopyridineingoatswithobstructiveurolithiasis AT rmcalistercounciltroche pharmacokineticsoforallyadministeredphenazopyridineingoatswithobstructiveurolithiasis AT jenniferdavis pharmacokineticsoforallyadministeredphenazopyridineingoatswithobstructiveurolithiasis AT derekmfoster pharmacokineticsoforallyadministeredphenazopyridineingoatswithobstructiveurolithiasis AT jenniferhalleran pharmacokineticsoforallyadministeredphenazopyridineingoatswithobstructiveurolithiasis |